The streak is alive: management narrates back-to-back quarters of the same improvement and shows this quarter extended i
The model's full reasoning — Q3 2016 call → NO我们根据提供的财报电话会议记录来判断。问题问的是管理层是否将本季度描述为连续改善序列中的最新一步,并明确连接了前几个季度,且有实际证据表明序列再次延长。 检查记录内容:管理层提到了多个方面的改善,但我们需要找到是否有明确的连续季度改善的表述。例如,在Term Life部分,提到“issued policies continue to experience exemplary growth, up 13% from the strong third quarter a year ago”,这是同比比较,没有明确说连续季度。在销售队伍方面,提到“life-licensed sales force grew 115,345 representatives at the end of the third quarter up 10% from the prior period and up 3% from the end of the second quarter”,这里明确提到了环比增长(up 3% from the end of the second quarter),但这是否构成“连续改善”的表述?管理层说“up 10% from the prior period”可能指同比,但“up 3% from the end of the second quarter”是环比。然而,问题要求的是“连续多个时期的改善”,并且要明确连接本季度与前一季度。这里提到了环比增长,但并没有说这是连续第几个季度。另外,在ISP部分,提到“our investment in savings products, our operating posted the first year-over-year quarterly gain in 2016”,这是同比,且是“first”,说明之前没有连续。 再仔细看,管理层在开头说“another strong quarter performance”,但“another”可能暗示连续,但并没有具体说连续改善。在Term Life部分,提到“issued policies continue to experience exemplary growth”,但“continue”可能暗示持续,但具体是同比还是环比?后面说“up 13% from the strong third quarter a year ago”,这是同比。没有明确说环比。 在销售队伍部分,明确说了“up 3% from the end of the second quarter”,这是环比,但这是否是连续改善?可能之前也有增长,但管理层没有明确说“连续第几个季度”。而且,问题要求“explicitly connecting this period to the immediately preceding period or periods as one continuing climb”,这里只提到了与第二季度的比较,但并没有说这是连续改善的一部分,也没有说“another quarter of growth”之类的。 另外,在Term Life的margin方面,提到“margins expanding to 20.1%”,但也没有说连续。 在DOL部分,没有涉及。 因此,管理层没有明确表述一个连续改善的序列,只是提到了环比增长,但并没有说这是连续第几个季度,也没有说“another consecutive quarter”之类的。而且,在ISP部分,明确说“first year-over-year quarterly gain”,说明之前没有连续。 所以,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| MFC | Manulife Financial Corporation | Q3 2023 | 2023-11-09 | C+ |
| BMBL | Bumble Inc. | Q3 2023 | 2023-11-07 | F |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| GRBK | Green Brick Partners, Inc. | Q3 2023 | 2023-11-01 | B |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| AEIS | Advanced Energy Industries, Inc. | Q2 2023 | 2023-08-03 | B |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| TSN | Tyson Foods, Inc. | Q2 2023 | 2023-05-08 | D |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| TGT | Target Corporation | Q4 2022 | 2023-02-28 | C |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| WRB | W. R. Berkley Corporation | Q1 2022 | 2022-04-26 | B |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| ALHC | Alignment Healthcare, Inc. | Q3 2021 | 2021-11-06 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| FMS | Fresenius Medical Care AG & Co. KGaA | Q2 2018 | 2018-07-31 | C |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| NOVT | Novanta Inc. | Q4 2017 | 2018-05-12 | B+ |
| EPC | Edgewell Personal Care Company | Q3 2017 | 2017-08-08 | D |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
MNKD · Q4 2023 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES The transcript explicitly frames the just-reported quarter as the second consecutive (or second successive) profitable quarter for the endocrine business unit and for the Company overall. Management ties this directly to actual results in the current period (net income of $1 million GAAP and $7 million non-GAAP in Q4) following the prior 2023 quarter, and states they will continue to focus on growing the profitability of the endocrine business unit, which has had a positive contribution for two straight quarters.
CYBR · Q3 2021 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES Udi Mokady explicitly frames Q3 as “another amazing quarter” that follows “an incredible second quarter,” using the single word “acceleration” to describe the quarter. He then quantifies the extension with concrete current-period metrics: subscription ARR growth accelerated to 131 % (reaching $139 million), total 38 % ARR growth (reaching $344 million), recurring revenue growth accelerated to 41 % ($89 million), and new logos accelerated to over 230.
MFC · Q3 2023 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES Roy Gori explicitly frames core ROE as having been ahead of the 15%+ medium-term target for the second consecutive quarter, while noting a 35% rise in core EPS this quarter (on top of steady year-on-year growth in core earnings over the past three quarters). Colin reinforces the sequential nature by stating that core ROE “increase[d] to 16.8%” this quarter.